Validation of the Meet-URO score in metastatic clear cell renal cell carcinoma patients receiving second or third-line tyrosine kinase inhibitors-immune checkpoint inhibitors combination therapy

• Sike He,
• Haoyang Liu,
• Junru Chen,
• Hao Zeng

Affiliations

Sike He

Department of Urology, Institute of Urology, West China Hospital, Sichuan University

Haoyang Liu

Department of Urology, Institute of Urology, West China Hospital, Sichuan University

Junru Chen

Department of Urology, Institute of Urology, West China Hospital, Sichuan University

Hao Zeng

Department of Urology, Institute of Urology, West China Hospital, Sichuan University